What you need to know about the new cairo drug – by Ephraim Shulevitz

Cairo is a pill that has the potential to save lives in a few months time.

This drug is being developed by a consortium of international pharmaceutical companies in collaboration with the government of Egypt.

This is the first time in history that a pharmaceutical has been approved by the Egyptian government, and it will have a dramatic impact on the lives of thousands of people in Egypt.

The drug is currently being studied in the US, but the drug has been licensed by the government in Egypt, where it is being tested.

This will be the first drug to be approved in the country in nearly 10 years, and this is not a coincidence.

Cairo has been tested in more than 100 countries, and there is a very good chance that it will become available in Egypt within a matter of months.

Egypt has the world’s largest population of people suffering from the debilitating Hepatitis C virus.

It is estimated that about 1 million Egyptians die each year from the virus, and more than half of these deaths are due to complications associated with the drug.

The World Health Organization estimates that by the end of 2020, at least 40 million people in the world will be infected with the virus.

The vast majority of those people will be in the developing world.

Caurol is an anti-Hepatitis drug, and will help to prevent a significant number of deaths and improve the lives for millions of people living with the disease.

It will also help people to improve their health and reduce the amount of COVID-19 in their bodies.

The news that CauroL will be available in the Egyptian market is a major news for everyone in Egypt and beyond.

It’s an important step forward in tackling this deadly disease.

We need more drugs in Egypt as the global pandemic continues to worsen, and as the country moves closer to reaching its goal of ending the pandemic by 2020.

If you are interested in getting more information on this, we recommend you visit our recent article.

Euphrates Shield Euphria Shield is a military and civilian-owned company.

It has been involved in many important projects in Egypt since the 1970s.

In 2016, the company was awarded a license to conduct clinical trials for the treatment of COV-19.

The trial has been going on since February 2018, and the results are expected to be released in March 2019.

The company has successfully conducted two phase III clinical trials, one in the United States and one in Canada.

The trials have been very successful, and are expected the results to be published in 2020.

It was also announced in 2016 that the company has received a $20 million grant from the US National Institutes of Health.

This grant will allow it to invest in additional research and development.

The US government is also supporting the Egyptian trials, which are also being conducted in other countries.

These include the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC), the World Health Organisation (WHO) and the United Nations Population Fund (UNFPA).

The European Medicine Agency EMA is responsible for regulating the use of medicines and pharmaceuticals in the European Union.

It coordinates EU drug policies and ensures the safety of medicines.

ECDC is the European Council of Ministers for the Protection of Human Rights and Fundamental Freedoms, and oversees EU-wide laws, regulations and policies.

EMA is a permanent council of EU institutions and is responsible for implementing all EU policies, legislation and regulation.

WHO is a United Nations agency that helps protect people from infectious diseases and other environmental hazards.

It develops and oversees policies, standards, and programs for the protection of human health and the environment.

The WHO is also the UN’s largest intergovernmental agency.

UNF PA The UNFPA is an independent non-governmental organisation that works for the benefit of the population and its interests.

The organisation was established in 1946 by the General Assembly of the United Nation to ensure the rights of people and peoples of the world.

It consists of more than 5,000 agencies that operate independently, and has more than 120,000 staff across the world working to achieve its main objectives.

Dr. Ibrahim Ibrahim, Head of the WHO Global Health Department, has been a member of the executive committee of the International Commission of Jurists since 2016.

He is also an Honorary Member of the ICJ.

Dr. Ibrahim is a leading expert in the field of infectious diseases, and was a founding member of WHO’s World Health Assembly and its Executive Committee.

It is important to note that the WHO is not just a global organisation that acts in a vacuum.

The Global Health Division at the WHO plays a crucial role in coordinating global efforts to contain the pandemics, and working with the WHO and other international agencies to make decisions on the use and distribution of medicines, vaccines, and other measures that will protect and enhance human health